Abstracts - PAGE Meeting (Population Approach Group Europe)

← Back to filters

Abstracts (64)

IV-01Alberto Russu

Integration of response, tolerability and dropout in flexible-dose trials: a case study in depression

Thursday 15:05-16:20

IV-02Tarjinder Sahota

Parameterisation of biomarker response in the assessment of long term safety

Thursday 15:05-16:20

IV-03Franziska Schädeli Stark

A semi-mechanistic population pharmacokinetic model for trastuzumab emtansine (T-DM1) antibody-drug conjugate and total antibody in patients with metastatic breast cancer (mBC)

Thursday 15:05-16:20

IV-04Andre Schäftlein

Comparison of elimination and absorption pharmacokinetics of linezolid in cystic fibrosis patients by three nonlinear models

Thursday 15:05-16:20

IV-05Rik Schoemaker

Modelling Ordered Categorical Allergic Rhinitis Scores in an Environmental Exposure Unit Study

Thursday 15:05-16:20

IV-06Nelleke Snelder

Quantitative understanding of drug effects on the interrelationship between mean arterial blood pressure, cardiac output and total peripheral resistance

Thursday 15:05-16:20

IV-07Yi SoJeong

Population Pharmacokinetics of a Novel Proton Pump Inhibitor, Drug Y, in Healthy Volunteers

Thursday 15:05-16:20

IV-08Alexander Solms

Modelling Inter-Individual Variability in PBPK Models and Deriving Mechanistic Covariate Models for PopPK

Thursday 15:05-16:20

IV-09

Applications of Population Pharmacokinetic Modeling during Phase2B to Support the Clinical Development of Dolutegravir (DTG, S/GSK1349572)

Thursday 15:05-16:20

IV-10

Dose Selection of Dolutegravir (DTG, S/GSK1349572) in Pediatric Studies

Thursday 15:05-16:20

IV-11Alexandre Sostelly

Characterization of the interaction between irinotecan, SN-38 and MBLI-87, a new BCRP inhibitor, with a multi-scale semi-mechanistic PKPD model

Thursday 15:05-16:20

IV-12Joe Standing

Methods for Optimising Neonatal Antimicrobial Use: Time- and Concentration-Dependent Agents

Thursday 15:05-16:20

IV-13Andreas Steingoetter

A population pharmacokinetic model for Gd-DTPA in DCE-MRI

Thursday 15:05-16:20

IV-14Doerthe Steller

Extension of Continuous-Time PK/PD Markov Models to Published Count Data

Thursday 15:05-16:20

IV-15Ahmed Suleiman

A Mixed-Effects Markov Model for Characterizing the Time Course of the Transitions between Different Extrapyramidal Side Effects Severity Levels

Thursday 15:05-16:20

IV-16Elin Svensson

Mega-model of nevirapine population pharmacokinetics

Thursday 15:05-16:20

IV-17

Applying of population PK-PD methods to analysis of viral dynamics of HIV/HCV-Coinfected Sustained Virological Responders and Nonresponders treated with PEG-IFN

Thursday 15:05-16:20

IV-18Ami Fazlin Syed Mohamed

Pharmacokinetic-Pharmacodynamic Modelling of Pre-existing and Emerging Resistance of Pseudomonas aeruginosa to Colistin

Thursday 15:05-16:20

IV-19Stina Syvänen

Quinidine Microdialysis Reveals Altered P-glycoprotein Function in Epileptic Rats in the Brain Parenchyma Rather than at the Blood-Brain Barrier

Thursday 15:05-16:20

IV-20Amit Taneja

Optimisation of Screening Experiments for the Assessment of Analgesic Effects

Thursday 15:05-16:20

IV-21Sonya Chapman

The Importance of Enterohepatic Recirculation in the Disposition of Pravastatin and Rosuvastatin: A Physiologically-Based Pharmacokinetic Modelling Approach

Thursday 15:05-16:20

IV-22David Ternant

Influence of the FcγRIIIa genetic polymorphism on the effect of antithymocyte globulins on lymphocyte populations in kidney transplantation

Thursday 15:05-16:20

IV-23Nadia Terranova

A non parametric population approach for selecting biomarkers of a drug action

Thursday 15:05-16:20

IV-24Donato Teutonico

Multivariate patient simulation for clinical trial optimization in COPD

Thursday 15:05-16:20

IV-25Michel Tod

A meta-analysis regression model for quantitative prediction of the impact of polymorphism on drug exposure

Thursday 15:05-16:20

IV-26

Evaluation of Circadian Rhythms in Hepatic CYP3A4 Activity Using Population Pharmacokinetics of Midazolam

Thursday 15:05-16:20

IV-27Mirjam Trame

Busulfan Dosing in Children: Body Weight versus Body Surface Area or Allometric Body Weight Dosing

Thursday 15:05-16:20

IV-29

Evaluating Bootstrap Methods in Nonlinear Mixed Effect Models (NMEM) Using a PK Model

Thursday 15:05-16:20

IV-30

A pharmacokinetic/pharmacodynamic analysis of central and peripheral effects of GSK3 inhibitors

Thursday 15:05-16:20

IV-31Wanchana Ungphakorn

Population Pharmacokinetics and Use of Monte Carlo Simulation To Determine Optimal Dosing Regimen of Oral Ciprofloxacin in Paediatric Patients with Severe Malnutrition

Thursday 15:05-16:20

IV-32Pavan Vajjah

Effect of decontamination on the pharmacokinetics and pharmacodynamics of venlafaxine in overdose

Thursday 15:05-16:20

IV-33Pyry Välitalo

Pharmacokinetics of Oxycodone in Labouring Women With Preliminary Estimates of Neonatal Exposure

Thursday 15:05-16:20

IV-34Marta Valle

Effect of Ritonavir Concentrations on Atazanavir Pharmacokinetics: Population Pharmacokinetic Analysis

Thursday 15:05-16:20

IV-35Georgia Valsami

Assessment of dosage regimens of tigecycline in hospitalised patients

Thursday 15:05-16:20

IV-36

Towards a Thorough Preclinical QT (“TpQT”) study paradigm: Pharmacokinetic-Pharmacodynamic (PKPD) Modelling of QTc Effects of Moxifloxacin in Cynomolgus Monkeys

Thursday 15:05-16:20

IV-37

Application of a Multiscale Physiologically-Based Bone and Calcium Systems Model to Guide the Development of GnRH receptor modulators for the Management of Endometriosis

Thursday 15:05-16:20

IV-38Jan-Stefan van der Walt

The effect of nevirapine-based antiretroviral therapy on the population pharmacokinetics of artemether and dihydroartemesinin in HIV-infected adults

Thursday 15:05-16:20

IV-39Sven van Dijkman

Optimal design for a dexmedetomidine pharmacokinetic trial in mechanically ventilated neonates with single organ respiratory failure.

Thursday 15:05-16:20

IV-40Erno van Schaick

PK-PD modelling of bone density and turnover effects of denosumab based on a circular model of bone remodelling

Thursday 15:05-16:20

IV-41Georgios Vlasakakis

The impact of modified-release formulations on bridging of pharmacokinetic data from adults to children

Thursday 15:05-16:20

IV-42Max von Kleist

A Mathematical Modelling Framework to Assess the Impact of Nevirapine-based Prophylaxis on vertical HIV Transmission

Thursday 15:05-16:20

IV-43Camille Vong

Optimal Design of Anticancer Regimens

Thursday 15:05-16:20

IV-44Katarina Vučićević

Population Pharmacokinetic Modelling of Amikacin in Neonates

Thursday 15:05-16:20

IV-45Toshihiro Wajima

Pharmacokinetic/pharmacodynamic Modeling and Long-term Simulation of Dolutegravir (DTG, S/GSK1349572) in Integrase Resistant Patients with a Simple Viral Dynamic Model

Thursday 15:05-16:20

IV-46Chenguang Wang

The allometric exponent for propofol clearance varies with age

Thursday 15:05-16:20

IV-47Thomas Wendl

Development of a physiologically-based pharmacokinetic (PBPK) model for Moxifloxacin and its metabolites in healthy adults

Thursday 15:05-16:20

IV-48Thomas Wendl

Modeling of renal failure, dialysis, inhalation and mechanical ventilation: Development of a whole-body physiologically-based pharmacokinetic (PBPK) model for ICU patients with and without renal failure receiving inhalatively administered Amikacin via a tracheal tube.

Thursday 15:05-16:20

IV-49Pawel Wiczling

Pharmacokinetics and Pharmacodynamics of Propofol in ASA III Patients Undergoing Abdominal Aortic Surgery

Thursday 15:05-16:20

IV-50Mélanie Wilbaux

Population K-PD modeling of CA125 and tumor size kinetics in relapsed ovarian cancer patients

Thursday 15:05-16:20

IV-51Christian Woloch

Population Pharmacokinetics of Mefloquine and its Major Metabolite in Healthy Volunteers.

Thursday 15:05-16:20

IV-52Dan Wright

Development of a Bayesian forecasting method for warfarin dose individualisation

Thursday 15:05-16:20

IV-53Rujia Xie

Model based meta-analysis (MBMA) to support the development of decision criteria in dental pain studies

Thursday 15:05-16:20

IV-54

Mechanism-based Modelling of the Antagonism between Polymyxin B and Levofloxacin against Pseudomonas aeruginosa using Mono- and Combination Therapy

Thursday 15:05-16:20

IV-55Shuying Yang

Predicting long term Placebo response based on short term observations:Meta-Analysis on FEV1 Response in Asthma Trials

Thursday 15:05-16:20

IV-56Shuying Yang

Using Placebo FEV1 Response to Improve the efficiency of clinical trials in Asthma

Thursday 15:05-16:20

IV-57James Yates

Population PK/PD modelling of AZD9773 in patients with severe sepsis.

Thursday 15:05-16:20

IV-58James Yates

Characterisation of Xenograft Response to Docetaxel by Nonlinear Mixed Effects Modelling

Thursday 15:05-16:20

IV-59

Semi-mechanistic PK/PD Model of the Effect of Odanacatib, a Cathepsin K Inhibitor, on Bone Turnover to Characterize Lumbar Spine and Distal Forearm Bone Mineral Density in A Phase IIb Study of Postmenopausal Women

Thursday 15:05-16:20

IV-61Miren Zamacona

Model based approach to inform early clinical development for a biologic

Thursday 15:05-16:20

IV-62Chao Zhang

Population Pharmacokinetics of Lopinavir and Ritonavir in Combination with Rifampicin-based Antitubercular Treatment in HIV-infected Adults

Thursday 15:05-16:20

IV-63Jianping Zhang

Population Pharmacokinetics of Lapatinib in Cancer Patients

Thursday 15:05-16:20

IV-64

Individualized therapy and Bayesian estimator of ganciclovir exposure after oral administration of valganciclovir in pediatric renal transplant patients

Thursday 15:05-16:20

IV-65Kirill Zhudenkov

Pharmacokinetics of PEG-IFN Alpha in HCV Infected Patients

Thursday 15:05-16:20

IV-66Simbarashe Peter Zvada

Population Pharmacokinetics of Isoniazid in Children with Pulmonary Tuberculosis

Thursday 15:05-16:20